Literature DB >> 27161940

Health policy: Affordability of drugs used in oncology health care.

Stefan Sleijfer1, Jaap Verweij2.   

Abstract

Mesh：

Year:  2016        PMID： 27161940     DOI： 10.1038/nrclinonc.2016.77

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly.

Authors:  Pieter van Eijsden
Journal:  BMJ       Date:  2015-12-15

2.  Actual costs of cancer drugs in 15 European countries.

Authors:  Wim H van Harten; Anke Wind; Paolo de Paoli; Mahasti Saghatchian; Simon Oberst
Journal:  Lancet Oncol       Date:  2015-12-04       Impact factor: 41.316

3.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

Review 4.  Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment?

Authors:  Nick Beije; Agnes Jager; Stefan Sleijfer
Journal:  Cancer Treat Rev       Date:  2014-12-23       Impact factor: 12.111

Review 5.  Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

Authors:  Marie-Therese Sickinger; Bastian von Tresckow; Carsten Kobe; Andreas Engert; Peter Borchmann; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 6.  Designing transformative clinical trials in the cancer genome era.

Authors:  Stefan Sleijfer; Jan Bogaerts; Lillian L Siu
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

7.  Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.

Authors:  Diwakar Davar; Mark A Socinski; Sanja Dacic; Timothy F Burns
Journal:  Exp Hematol Oncol       Date:  2015-12-14
  7 in total
  2 in total

1.  Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives.

Authors:  Aniek Dane; Soedaba Ashraf; James Timmis; Monique Bos; Carin Uyl-de Groot; P Hugo M van der Kuy
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

Review 2.  Facing the Global Challenges of Access to Cancer Medication.

Authors:  Abdul Raman Jazieh; Abdulaziz H Al-Saggabi; Mark McClung; Robert Carlson; Lowell E Schnipper; Alexandru Eniu; Barri Blauvelt; Yousuf Zafar; David Kerr
Journal:  J Glob Oncol       Date:  2018-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.